Loading
Life sciences · Phase 2 Trial
ClinicalTrials.gov · September 24, 2026
No summary has been generated for this record yet. What follows is drawn from its source metadata only.
Phase 2 Trial.
No findings were extractable from the material analysed.
Safety was not reported in the material analysed. Check the source before drawing any conclusion about harm.
The source did not state who this applies to in practice.
Graded across the dimensions that decide whether you should act, each from what the source actually supports. There is no single score, and where a dimension was not assessed it says so.
This record has not been graded across any dimension yet. Treat the label above as provisional and read the source.
What is missing. This record has no bottom line, key findings, reported figures, evidence dimensions. That is a gap in the analysis, not a judgement about the study.
Registry record from ClinicalTrials.gov (NCT06017609). This is a study registration, not published results. Lead sponsor: Akros Pharma Inc.. Recruitment status: COMPLETED. Phase: PHASE2. Study type: INTERVENTIONAL. Enrollment: 314 participants (ACTUAL). Conditions: Chronic Heart Failure. Interventions: DRUG: JTT-861 Capsules; DRUG: Placebo Capsules. Primary outcome measures: Change from baseline to end of treatment (EOT) in left ventricular ejection fraction (LVEF) as assessed by two-dimensional echocardiography (2D-echo) , 12 Weeks; Change from baseline to EOT in left ventricular end-systolic volume (LVESV) index as assessed by 2D-echo , 12 Weeks; Change from baseline to EOT in left ventricular end-diastolic volume (LVEDV) index as assessed by 2D-echo , 12 Weeks; Change from baseline to EOT in left atrial volume (LAV) as assessed by 2D-echo , 12 Weeks; Change from baseline to EOT in N-terminal pro b-type natriuretic peptide (NT-pro-BNP) values , 12 Weeks; Change in Kansas City Cardiomyopathy Questionnaire (KCCQ) scores from baseline , 16 Weeks; Number of subjects with treatment-emergent adverse events , Up to 16 Weeks; Trough plasma concentrations of JTT-861 , Weeks 4, 8 and 12; Post-dose plasma concentrations of JTT-861 , Weeks 2, 4 and 8. Brief summary: This study will evaluate the efficacy, safety, tolerability and pharmacokinetics of JTT-861 administered once daily for 12 weeks in subjects with heart failure with reduced ejection fraction (HFrEF) who are on a stable, guideline-directed medical therapy for heart failure.